With its leading research product, the actinic keratosis therapy Picato (ingenol mebutate) gel, recommended for approval in Europe Sept. 20 by the European Medicine Agency’s key Committee for Medicinal Products for Human Use, or CHMP, and after a 60% jump in headcount over the past four years, Denmark’s Leo Pharma AS is looking for new collaborations, partnerships and acquisitions to fuel the next stage of its global expansion program.
Leo acquired the rights to Picato from the Australian/U.S. company Peplin Ltd., which it bought for $287.5 million in...